The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients
References (15)
- et al.
Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis
Clin Infect Dis
(2003) - et al.
Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysis
Med J Aust
(2001) - et al.
Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia
Clin Infect Dis
(2007) - et al.
Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study
Medicine (Baltim)
(2003) - et al.
Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus
N Engl J Med
(2006) - et al.
Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae
Antimicrob Agents Chemother
(2010) - et al.
CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections
J Antimicrob Chemother
(2010)
Cited by (91)
Off-label use versus formal recommendations of conventional and novel antibiotics for the treatment of infections caused by multidrug-resistant bacteria
2023, International Journal of Antimicrobial AgentsCeftaroline activity against Staphylococcus aureus isolated from patients with infective endocarditis, worldwide (2010–2019)
2021, International Journal of Infectious DiseasesOff-label use of ceftaroline fosamil: A systematic review
2019, International Journal of Antimicrobial AgentsCitation Excerpt :Ceftaroline dose adjustment is indicated for CrCL ≤ 50 mL/min [33]. As reported in Table 1, 12 of the selected studies utilized the 600 mg q8 dose [10,12–16,18,20,26,27,29,31] and three the 800 mg q12 dose [16,20,26] (Table 3). In the case series of bacterial meningitis reported by Sakoulas and colleagues, the only case with unfavorable outcome received a dose of 600 mg q 12 h (the dose approved for ABSSS and CABP) whereas the 4 successful cases received 600 mg q 8 h, indicating a better penetration of CSF at the three times a day (TID) dose [32].
Synergistic antibacterial mechanism of Bi <inf>2</inf> Te <inf>3</inf> nanoparticles combined with the ineffective β-lactam antibiotic cefotaxime against methicillin-resistant Staphylococcus aureus
2019, Journal of Inorganic BiochemistryCitation Excerpt :Multidrug-resistant (MDR) pathogens pose a substantial threat to public health [1–3]. Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most prevalent MDR pathogens worldwide, causing pneumonia, skin infection, osteomyelitis and bacteremia and exhibiting remarkable resistance to multiple antibiotic treatments [4–8]. However, the development of new antibiotics is vastly outpaced by current therapies that are losing efficacy [9–12].
Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience
2019, International Journal of Antimicrobial AgentsDaptomycin for the treatment of Staphylococcus aureus infections complicated by septic pulmonary emboli
2019, Diagnostic Microbiology and Infectious DiseaseCitation Excerpt :Trimethoprim-sulfamethoxazole is frequently active in vitro against MRSA; however, it was inferior to vancomycin in a randomized controlled trial of intravenous drug users with severe staphylococcal infections (Markowitz et al., 1992). Ceftaroline is a promising new antibiotic with preliminary data demonstrating efficacy in complicated S. aureus infections; however, there are currently insufficient data to recommend routine use in IE (Casapao et al., 2014; Ho et al., 2012; Lin et al., 2013; Zasowski et al., 2017). Daptomycin in combination with beta-lactams, including ceftaroline, or trimethoprim-sulfamethoxazole may be useful in salvage therapy; however, available outcomes data are limited.